SymKardia, Inc. — SEC Form D Filing

SymKardia, Inc. filed an SEC Form D on June 18, 2026, reporting $500K raised in Medical Devices.

Form D filing details

Filing
SEC Form D
Filing date
June 18, 2026
Amount reported
$500K
Round stage
Pre-Seed
Industry
Medical Devices
Website
https://www.symkardia.com/

What the company does

Securities: Debt. Exemption: Rule 506(b). Incorporated: DELAWARE

Problem

Cardiac arrhythmias are a condition that needs improved treatment methods, as current approved therapies are limited to targeting only the cardiac tissue.

Solution

SymKardia is developing a method of selective cardiac neuromodulation to treat cardiac arrhythmias.

Verdict

Investors backed this pre-seed round because the proposed neurological angle offered a novel pathway for a widespread cardiac condition, not because the technology itself was proven. The implicit bet was on the potential for a new mechanism of action to unlock better patient outcomes, assuming basic biological feasibility. The limited upside stemmed from the early stage of scientific validation and the long, capital-intensive road inherent in medical device development requiring extensive clinical trials and regulatory hurdles.

Source: SEC EDGAR Form D filing